I2TC34 Stock Overview
A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Intra-Cellular Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$84.24 |
| 52 Week High | US$85.98 |
| 52 Week Low | US$60.83 |
| Beta | 0.70 |
| 1 Month Change | 1.06% |
| 3 Month Change | 26.43% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 72.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| I2TC34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 0% | 3.6% | -1.3% |
| 1Y | n/a | -27.3% | -14.2% |
Return vs Industry: Insufficient data to determine how I2TC34 performed against the BR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how I2TC34 performed against the BR Market.
Price Volatility
| I2TC34 volatility | |
|---|---|
| I2TC34 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 9.7% |
| 10% least volatile stocks in BR Market | 2.9% |
Stable Share Price: I2TC34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine I2TC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 610 | Sharon Mates | www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
Intra-Cellular Therapies, Inc. Fundamentals Summary
| I2TC34 fundamental statistics | |
|---|---|
| Market cap | R$56.36b |
| Earnings (TTM) | -R$533.90m |
| Revenue (TTM) | R$3.79b |
14.9x
P/S Ratio-105.6x
P/E RatioIs I2TC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I2TC34 income statement (TTM) | |
|---|---|
| Revenue | US$613.73m |
| Cost of Revenue | US$263.87m |
| Gross Profit | US$349.86m |
| Other Expenses | US$436.23m |
| Earnings | -US$86.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 57.01% |
| Net Profit Margin | -14.07% |
| Debt/Equity Ratio | 0% |
How did I2TC34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 21:41 |
| End of Day Share Price | 2024/12/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Intra-Cellular Therapies, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |
| Jason Matthew Gerberry | BofA Global Research |